



February 14, 2018

Company name: SanBio Co., Ltd.

Representative: Keita Mori, Representative Director
and President

(TSE Mothers Code: 4592)

Contact: Yoshihiro Kakutani, Corporate
Officer of Management
Administration
(TEL. +81-3-6264-3481)

SanBio Initiates Development Program of Regenerative Therapy for Chronic Stroke using SB623 in Japan

SanBio Co., Ltd. (Headquarters: Chuo-ku, Tokyo; Representative Director and President: Keita Mori, hereafter "the Company") announced today that following the Company's termination of its licensing agreement with Teijin Limited (see separate press release dated February 14, 2018), SanBio is preparing an expedited development program of regenerative therapy for chronic stroke using SB623 in Japan, in order to obtain marketing approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) at the earliest possible time. Details of the program and the schedule will be announced as soon as they are available.

The impact of this event on the Company's financial results for the fiscal year ending January 31, 2019, will be examined. If any matters need to be disclosed, the Company will announce them promptly.